Using the structure provided by the well-described cancer–immunity cycle, scientists outline the key steps required for a successful antitumour immune response in the context of renal cell carcinoma, and describe the development of promising new immunotherapies within the context of this framework.
[Nature Reviews Clinical Oncology]
6445218
{6445218:8EATWYWD}
apa
50
1
157879
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-8a9fb0e8cb3947254bb522e03160e91b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228EATWYWD%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Braun%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBraun%2C%20D.%20A.%2C%20Bakouny%2C%20Z.%2C%20Hirsch%2C%20L.%2C%20Flippot%2C%20R.%2C%20Van%20Allen%2C%20E.%20M.%2C%20Wu%2C%20C.%20J.%2C%20%26amp%3B%20Choueiri%2C%20T.%20K.%20%282021%29.%20Beyond%20conventional%20immune-checkpoint%20inhibition%20%26%23x2014%3B%20novel%20immunotherapies%20for%20renal%20cell%20carcinoma.%20%3Ci%3ENature%20Reviews%20Clinical%20Oncology%3C%5C%2Fi%3E%2C%201%26%23x2013%3B16.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-020-00455-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-020-00455-z%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3D8EATWYWD%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Beyond%20conventional%20immune-checkpoint%20inhibition%20%5Cu2014%20novel%20immunotherapies%20for%20renal%20cell%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziad%22%2C%22lastName%22%3A%22Bakouny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Flippot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliezer%20M.%22%2C%22lastName%22%3A%22Van%20Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toni%20K.%22%2C%22lastName%22%3A%22Choueiri%22%7D%5D%2C%22abstractNote%22%3A%22The%20management%20of%20advanced-stage%20renal%20cell%20carcinoma%20%28RCC%29%20has%20been%20transformed%20by%20the%20development%20of%20immune-checkpoint%20inhibitors%20%28ICIs%29.%20Nonetheless%2C%20most%20patients%20do%20not%20derive%20durable%20clinical%20benefit%20from%20these%20agents.%20Importantly%2C%20unlike%20other%20immunotherapy-responsive%20solid%20tumours%2C%20most%20RCCs%20have%20only%20a%20moderate%20mutational%20burden%2C%20and%20paradoxically%2C%20high%20levels%20of%20tumour%20CD8%2B%20T%20cell%20infiltration%20are%20associated%20with%20a%20worse%20prognosis%20in%20patients%20with%20this%20disease.%20Building%20on%20the%20successes%20of%20antibodies%20targeting%20the%20PD-1%20and%20CTLA4%20immune%20checkpoints%2C%20multiple%20innovative%20immunotherapies%20are%20now%20in%20clinical%20development%20for%20the%20treatment%20of%20patients%20with%20RCC%2C%20including%20ICIs%20with%20novel%20targets%2C%20co-stimulatory%20pathway%20agonists%2C%20modified%20cytokines%2C%20metabolic%20pathway%20modulators%2C%20cell%20therapies%20and%20therapeutic%20vaccines.%20However%2C%20the%20successful%20development%20of%20such%20novel%20immune-based%20treatments%20and%20of%20immunotherapy-based%20combinations%20will%20require%20a%20disease-specific%20framework%20that%20incorporates%20a%20deep%20understanding%20of%20RCC%20immunobiology.%20In%20this%20Review%2C%20using%20the%20structure%20provided%20by%20the%20well-described%20cancer%5Cu2013immunity%20cycle%2C%20we%20outline%20the%20key%20steps%20required%20for%20a%20successful%20antitumour%20immune%20response%20in%20the%20context%20of%20RCC%2C%20and%20describe%20the%20development%20of%20promising%20new%20immunotherapies%20within%20the%20context%20of%20this%20framework.%20With%20this%20approach%2C%20we%20summarize%20and%20analyse%20the%20most%20encouraging%20targets%20of%20novel%20immune-based%20therapies%20within%20the%20RCC%20microenvironment%2C%20and%20review%20the%20landscape%20of%20emerging%20antigen-directed%20therapies%20for%20this%20disease.%22%2C%22date%22%3A%222021-01-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41571-020-00455-z%22%2C%22ISSN%22%3A%221759-4782%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41571-020-00455-z%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-01-13T00%3A52%3A32Z%22%7D%7D%5D%7D
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021). Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 1–16. https://doi.org/10.1038/s41571-020-00455-z Cite
